Worm infestation in intestine has a remote effect on viral defenses
Infection with parasitic intestinal worms (helminths) can apparently cause sexually transmitted viral infections to be much more severe elsewhere in the body.
Infection with parasitic intestinal worms (helminths) can apparently cause sexually transmitted viral infections to be much more severe elsewhere in the body.
Johnson & Johnson Statement on COVID-19 Vaccine (Updated) :The safety and well-being of the people who use our products is a number one priority. We are aware of… read more.
Financial stress can have an immediate impact on well-being, but can it lead to physical pain nearly 30 years later? The answer is yes, according to new research… read more.
Oncopeptides AB announced that the Company has submitted an application to the European Medicines Agency, EMA, for conditional marketing authorization of melflufen (melphalan flufenamide) in the EU, based… read more.
A hypothesis has been put forward as to why COVID-19 Vaccine AstraZeneca (ChAdOx1 nCov-19) seems to trigger an abnormal and potentially life-threatening combination of blood clotting and low… read more.
Gilead Sciences, Inc. announced that the FDA has granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)… read more.
FibroGen, Inc. has provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase III program for the treatment of anemia of chronic… read more.
After an appendectomy, a quarter (24.8%) of all children wanted a stronger pain treatment in the first 24 hours after their operation. Among children who had a tonsillectomy,… read more.
Merck Inc., announced that the FDA has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for Keytruda, the company’s anti-PD-1 therapy,… read more.
Roche announced that the European Commission (EC) has approved Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older,… read more.
As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.
Biogen announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of Tysabri (natalizumab) to treat relapsing-remitting multiple sclerosis (MS).
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.